伏立康唑是预防ifi的一线抗真菌制剂。
Voriconazole is the first-line antifungal agent for prevention of IFI.
早期诊断和口服伏立康唑治疗IA，患者死亡率在可接受的范围。
Early diagnosis and treatment of ia with oral voriconazole result in acceptable mortality rates.
目的：探讨伏立康唑治疗恶性血液病患者合并侵袭性真菌感染的结果。
Objective:To investigate the effects of voriconazole in patients with malignant hematological disorders complicated by invasive fungal infection.
应用推荐